1-Year Follow up to the 1473-IMIQ Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00114023
Recruitment Status : Completed
First Posted : June 14, 2005
Last Update Posted : February 19, 2007
Information provided by:
Graceway Pharmaceuticals, LLC

Brief Summary:
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Condition or disease Intervention/treatment
Keratosis Drug: Imiquimod 5% cream

Study Type : Observational
Enrollment : 84 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study
Study Start Date : January 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Imiquimod
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions

Exclusion Criteria:

  • Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00114023

United States, Arkansas
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC Identifier: NCT00114023     History of Changes
Other Study ID Numbers: 1518-IMIQ
First Posted: June 14, 2005    Key Record Dates
Last Update Posted: February 19, 2007
Last Verified: October 2006

Keywords provided by Graceway Pharmaceuticals, LLC:
Imiquimod 5% cream
3M Pharmaceuticals
Actinic Keratosis

Additional relevant MeSH terms:
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers